The April 2026 Department of Justice order, issued under President Trump’s December 2025 executive directive, immediately moved FDA-approved cannabis products and state-licensed medical marijuana into Schedule III of the Controlled Substances Act, effective April 28. This partial rescheduling addressed research and tax barriers for qualifying medical operators while leaving broader botanical cannabis in Schedule I pending further review. An expedited DEA administrative hearing begins June 29, 2026, to evaluate full reclassification to Schedule III through formal rulemaking, including public input and potential litigation. Trader focus centers on the hearing timeline, any resulting final rule, and whether procedural or legal challenges extend the process beyond current expectations for completion.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano$764,777 Wol.
Mar 31, 2026
June 30
2%
December 31
27%
$764,777 Wol.
June 30
$340,918 Wol.
2%
December 31
$158,977 Wol.
27%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The April 2026 Department of Justice order, issued under President Trump’s December 2025 executive directive, immediately moved FDA-approved cannabis products and state-licensed medical marijuana into Schedule III of the Controlled Substances Act, effective April 28. This partial rescheduling addressed research and tax barriers for qualifying medical operators while leaving broader botanical cannabis in Schedule I pending further review. An expedited DEA administrative hearing begins June 29, 2026, to evaluate full reclassification to Schedule III through formal rulemaking, including public input and potential litigation. Trader focus centers on the hearing timeline, any resulting final rule, and whether procedural or legal challenges extend the process beyond current expectations for completion.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Rynek otwarty: Feb 7, 2026, 5:04 PM ET
Wolumen
$764,777Data zakończenia
Mar 31, 2026Rynek otwarty
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The April 2026 Department of Justice order, issued under President Trump’s December 2025 executive directive, immediately moved FDA-approved cannabis products and state-licensed medical marijuana into Schedule III of the Controlled Substances Act, effective April 28. This partial rescheduling addressed research and tax barriers for qualifying medical operators while leaving broader botanical cannabis in Schedule I pending further review. An expedited DEA administrative hearing begins June 29, 2026, to evaluate full reclassification to Schedule III through formal rulemaking, including public input and potential litigation. Trader focus centers on the hearing timeline, any resulting final rule, and whether procedural or legal challenges extend the process beyond current expectations for completion.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Wolumen
$764,777Data zakończenia
Mar 31, 2026Rynek otwarty
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...The April 2026 Department of Justice order, issued under President Trump’s December 2025 executive directive, immediately moved FDA-approved cannabis products and state-licensed medical marijuana into Schedule III of the Controlled Substances Act, effective April 28. This partial rescheduling addressed research and tax barriers for qualifying medical operators while leaving broader botanical cannabis in Schedule I pending further review. An expedited DEA administrative hearing begins June 29, 2026, to evaluate full reclassification to Schedule III through formal rulemaking, including public input and potential litigation. Trader focus centers on the hearing timeline, any resulting final rule, and whether procedural or legal challenges extend the process beyond current expectations for completion.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano
Uważaj na linki zewnętrzne.
Uważaj na linki zewnętrzne.
Często zadawane pytania